Respiratory Medicines · LP-072
Salbutamol Inhaler
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-072Respiratory Medicines
- Generic identity
- SalbutamolInhaler
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-072
- Generic identity
- Salbutamol
- Presentation
- Inhaler
- Catalogue strength
- 100 mcg/dose
- Catalogue pack
- 200-dose metered-dose inhaler
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: salbutamol.
- Dosage form: inhaler.
- Catalogue dose expression: 100 mcg/dose.
- Catalogue pack/presentation: 200-dose metered-dose inhaler.
Layer 02 · Unresolved product-specific fields
- Exact inhaler model/platform, propellant/formulation and actuator specification.
- Whether 100 mcg/dose is metered/actuation content or delivered/emitted dose.
- Priming, cleaning, dose-counter, spacer compatibility and administration instructions.
- Approved indication, age range, storage, shelf life, registration and supply status.
Identity note
B01 issue P010 remains open. Device/model and dose-basis evidence are required before inhaler-specific claims can be finalised.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 100 mcg/dose | Metered-dose inhaler | — | 200-dose inhaler | Model and metered-versus-delivered dose basis are not identified by the catalogue. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Salbutamol, called albuterol in the United States, is a short-acting bronchodilator that relaxes airway smooth muscle. Oral and inhaled presentations have materially different delivery characteristics and are not interchangeable by volume or stated strength. Inhaled formulations are used in respiratory treatment plans; an oral syrup should not be portrayed as an equivalent rescue inhaler. This ingredient profile does not constitute an approved Luang Pharma respiratory indication.
Clinical context and therapeutic role
Respiratory symptoms require a diagnosis and a written plan appropriate to asthma, chronic obstructive pulmonary disease or another condition. Bronchodilation can relieve narrowing of the airways, but salbutamol does not replace anti-inflammatory treatment when that is needed. Increasing reliance on a reliever or decreasing benefit can signal deterioration. Severe breathlessness, inability to speak normally, bluish coloration or exhaustion needs urgent care rather than repeated unsupervised use.
Selected safety context
Tremor, headache, palpitations and a faster heartbeat may occur. Excess exposure can cause dangerous heart rhythm problems and low potassium. Worsening wheeze immediately after inhalation may represent paradoxical bronchospasm and needs urgent review. Heart disease, thyroid disease, diabetes and interacting medicines should be considered. The prescribed device or formulation and its instructions must be followed. An oral product should never be substituted into a nebulizer or inhaler.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue identifies an inhaler, but the exact device technology, formulation and delivered-versus-metered dose basis require confirmation. Patient technique and device compatibility materially affect delivery. A stated amount per actuation is not proof of equivalence between different inhalers, nor of compatibility with a particular spacer.
Follow the supplied instructions for priming, cleaning, dose counting and storage. Keep any protective cap in place as directed and inspect the device for damage. A pharmacist or trained professional should demonstrate technique; device components should not be substituted across manufacturers without confirmation.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A respiratory-care professional should verify the diagnosis, inhaled-versus-oral role, exact device and technique where applicable. The patient requires a clear plan for worsening symptoms, with regular review of control and adverse effects.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Model-specific approved label/leaflet and inhaler technical specification.
Dose-basis evidence distinguishing metered from delivered/emitted dose.
Device/actuator, priming, cleaning and compatibility documentation.
Registration/market-status evidence for the exact inhaler presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07a checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| DailyMed: Albuterol sulfate inhalation aerosolArchived source classification: US official drug label example | Source revision recorded: Label updated 20 May 2026; Archived access check: 2026-09-11 | Comparator official MDI label; it illustrates device-specific dose/presentation documentation and does not identify LP-072. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-072.
Professional enquiries
Request product-specific evidence for LP-072.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.